Overview of antibiotic use and resistance: Setting the stage for tigecycline

Clinical Infectious Diseases

Volumn 41, Issue 5 SUPPL., 2005, Pages

  Zinner, Stephen H ^a  

^a MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; STREPTOGRAMIN; SULFONAMIDE; SULTAMICILLIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG;

ACINETOBACTER; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTEROIDES FRAGILIS; BLOOD TOXICITY; EDITORIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FATTY LIVER; GONORRHEA; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; LEGIONNAIRE DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; NAUSEA; NEUTROPENIA; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; PROTEUS MIRABILIS; RESPIRATORY TRACT INFECTION; SEPSIS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; HUMANS; MINOCYCLINE;

EID: 23844446715     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431670     Document Type: Editorial

References (19)

1. Lepper MH, Wolfe CK, Zimmerman HJ, et al. Effect of large doses of aureomycin on human liver. AMA Arch Intern Med 1951;88:271-83.
2. Yunis AA. Chloramphenicol-induced bone marrow suppression. Semin Hematol 1973; 10:225-34.
3. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-8.
4. Lipsitch M. Fears growing over bacteria resistant to antibiotics. New York Times, 12 September 1995:C1.
5. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-82.
6. Naim TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infections. JAMA 2003; 290: 2976-84.
7. Kazakova SV, Hageman JC, Matova M, et al. A clone of methicillin- resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352:468-75.
8. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
9. Sakoulas G, Moise-Broder PA, Schentag J, Forest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity and efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402.
10. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7.
11. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337:441-6.
12. Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin Infect Dis 2004; 38(Suppl 4): S357-62.
13. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005; 40:1087-93.
14. Stein GE. Safety of newer parenteral antibiotics. Clin Infect Dis 2005;41 (Suppl 5): S293-302.
15. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5):S303-14.
16. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 (Suppl 5):S315-32.
17. Meagher AK, Ambrose P, Grasela TH, and Ellis-Gross EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41(Suppl 5):S333-40.
18. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. Tigecycline 300 and 305 cSSSI Study Groups. The efficacy and safety of tigecycline for the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5): S341-53.
19. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. Tigecycline 301 and 306 Study Groups. The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(Suppl 5): S354-67.